Remove tag new-category
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

Breakthrough designations can speed up the development of new therapies, making them available to patients sooner. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on. It is well-established for conventional drugs and medical devices but has only recently started to be used for DTx.

article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Cannabinoid receptors fall into two categories: CB1 and CB2 receptors. Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

The unmet needs can be grouped into the broad categories of efficacy-related needs, cost-related needs, toxicity-related needs, personalised care-related needs, and “other” needs. Combining data from all markets, efficacy-related needs were identified as the most important unmet needs category.

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Both drugs come with a high price tag. In its past statements shared with other outlets, Amgen stated that patents need to give researchers wide protection to incentivise new inventions. Enablement as the crux of the case Amgen could win at the Supreme Court, says Shahrokh Falati, professor of law at the New York Law School.

104
104
article thumbnail

2021 Highlights of Chronic Care Medicine

PharmD Live

CPA healthcare analysts at the Tennessee firm PYA calculated the pay differences in 11 categories of reimbursement for CCM, Complex CCM, and PCM. With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. The average of the increases is 49%.